To evaluate the etiology and treatment results of retinal vein occlusion

PURPOSE: To evaluate the etiology and treatment results of retinal vein occlusion patients.MATERİAL AND METHODS: One hundred and thirty eight eyes of 138 patients who were examined diagnosis of with RVO at Dicle University Medical Faculty Eye Clinic between 2006 - 2010. The age, gender, systemic disease, ocular disease, affected eye, type of involvement, the first application period, the application of visual acuity and final visit, visual acuity, eye pressure application, the last visit, eye pressure, follow-up period, treatment (Intravitreal Bevacizumab injection, focal-grid laser) were evaluated. Patients were examined by optical coherence tomography, fundus flourescein angiography, biomicroscopic fundus examination, corrected visual acuity was assessed with the Snellen chart. Patients with chronic macular edema intravitreal Bevacizumab and / or grid laser photocoagulation was performed . Panretinal laser photocoagulation was performed to ischemic type RVO patients. Patients with ischemic type RVO focal laser photocoagulation was applied to widesperad non-perfusion areas and neovascularization areas. In this study the etiopathogenesis of RVO, laser photocoagulation and intravitreal Bevacizumab treatments and their effectiveness were compared and visual acuity and foveal thickness measured with OCT changes and clinical course of disease were assessedRESULTS: Seventy three of patienst were female and 65 of them were male. Our study, 21 out of 138 eyes with central retinal vein occlusion, branch retinal vein occlusion in 17 and 98 in the lower temporal and upper temporal branch vein occlusion was present in 2 hemicentral vein occlusion. Seventy one patients had RVO in the right ey and 67 had in the left eye. The median age was 58.9 years. The time between diagnosis and the first application was an average of 5.5 weeks. The mean follow-up period was 5.94 months. In 23 cases (16.6%) with type II diabetes mellitus, stand at 94 (68.1%), hypertension in 15 (10.8%), cardiovascular disease, in 4 (2.9%) asthma, and 18 patients (13%), hyperlipidemia disease had a history. Seven cases had glaucoma, 12 had DRP and 5 had ARMD. Fourty-two patients were performed with intravitreal injection of Bevacizumab, 5 patients underwent grid laser photocoagulation, 10 patients underwent Bevacizumab + grid laser photocoagulation, 5 patients underwent focal laser + grid laser, 26 patients underwent grid+panretinal laser photocoagulation and 50 patients were followed without any treatment. The treatments patients and untreated patients were followed between the first and last visit and there was a statistically significant difference (p <0.05) at visual acuity values. Visual acuity values of the patients with grid+focal laser and focal+ panretinal between the first and last visit, there was no statistically significant difference (p> 0.05). At all patients between the first and last visit there was a statistically significant difference (p <0.05) at CFT values. The VA were increased to 60% in LFK grid group and 57% in intravitreal Bevacizumab group and 48% in untreated group respectively . CFT decreased in all groups, showed an increase in visual acuity, there was no statistically significant relationship between reduction in CFT and VA .CONCLUSION: Argon laser treatment and intravitreal Bevacizumab injection have favorable effects on both the anatomical and functional success at retinal vein occlusion.KEYWORDS: Retinal vein occlusion, Risk factors, Macular edema, Laser photocoagulation, Anti-vascular endothelial growth factors, Visual prognosis